Doxifluridine as palliative treatment in advanced gastric and pancreatic cancer patients

Oncology (Switzerland)

Volumn 53, Issue 1, 1996, Pages 54-57

  Bartolomeo, Maria Di ^a   Bajetta, Emilio ^a   Somma, Luisa ^a   Carnaghi, Carlo ^a   Bandieri, Elena ^a   Del Vecchio, Michele ^a   Stampino, Corrado Gallo ^a   Buzzoni, Roberto ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Chemotherapy; Doxifluridine; Fluoropyrimidine; Gastric cancer; Pancreatic cancer

Indexed keywords

DOXIFLURIDINE; FOLINATE CALCIUM; FOLINIC ACID;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER REGRESSION; CLINICAL TRIAL; DIARRHEA; DRUG CYTOTOXICITY; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA; ORAL DRUG ADMINISTRATION; PANCREAS CANCER; PRIORITY JOURNAL; STOMACH CANCER; STOMACH PAIN; SURVIVAL TIME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; FEMALE; FLOXURIDINE; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PALLIATIVE CARE; PANCREATIC NEOPLASMS; PRODRUGS; STOMACH NEOPLASMS;

EID: 0030025156     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000227535     Document Type: Article

References (20)

1. Cook AF, Holman MJ: Fluorinated pyrimidine nucleosides. 3. Synthesis and antitumour activity of a series of 5'-deoxy-5-fluoropyrimidine nucleosides. J MedChem 1979;22:1330-1335.
2. Bollag W, Hartmann HR: Tumor inhibitory effects of a new fluorouracil derivative: 5'-Deoxy-5-fluorouridinc. Eur J Cancer 1980; 16: 427-432.
3. Olver IN, Reece PA, Bishop JF, Morris G, Hill-Coat BL, Guentert WT: A phase I study of doxifluridinc as a five-day stepped-dose continuous infusion. Am J Clin Oncol 1990; 13:308-311.
4. Bajetta E, Colleoni M, Rosso R, Sobrero A, Amadori D, Cornelia G, Marangolo M, Scanni A: Prospective randomized trial comparing fluorouracil versus doxifluridine for the treatment of advanced colorectal cancer. Eur J Cancer 1993;12:1658-1663.
5. Shimizu E, Saijo N, Eguchi K, Shinkai T, Tomigaga K, Sasaki Y, Fujita J: Phase II study of oral administration of 5'-deoxy-5-fluorouri-dine (5'-DFUR) for solid tumors. Jpn J Clin Oncol 1984;14:679-683.
6. Abele R, Alberto P, Kaplan S, Siegenthaler P, Hofmann V, Ryssel HJ, Hartmann D, Holdener EF., Cavalli F: Phase II study of doxifluridinc in advanced colorectal adenocarcinoma. J Clin Oncol 1983;12:750-754.
7. Kurihara M: Chemotherapy in gastric cancer, in Nishi M, Ichikawa H, Nakajima T (eds): Gastric Cancer. Hong Kong, Springer, 1993.
8. Ota K: Multicentre cooperative phase II study of 5'-dcoxy-5-fluorouridinc in the treatment of colorectal cancer. J Int Med Res 1988; 16:19B-20B.
9. Bajetta E, Di Bartolomeo M, de Braud F, Bozzetti F, Bochicchio AM, Cornelia P, Fagnani D. Farina G, Ferroni C, Franchi R, Gebbia V, Ian-niello G, brillo A, Pinotti G, Schieppati G, Ucci G, Visini M, Zaniboni A, Buzzoni R, Casartelli C, Nelli P: Etoposidc, doxorubicin and cisplatin (EAP) treatment in advanced gastric carcinoma: A multicentre study of the Italian trials in medical oncology (ITMO) group. Eur J Cancer 1994;5:596-600.
10. Di Bartolomeo M, Bajetta E, de Braud F, Bochicchio AM, Gebbia V, Bozzetti F, Doci R, Bonfanti G, Cozzaglio L: Phase II study of etoposidc. leucovorin and fluorouracil for patients with advanced gastric cancer unsuitable for aggressive chemotherapy. Oncology 1995;52: 41-44.
11. Cullinan SA, Moertel CG, Fleming TR, Rubin JR, Krook JE, Everson LK, Windschitl HE: A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. JAMA 1985;253:2061-2067.
12. Warshaw AL, Del Castillo FC: Pancreatic carcinoma. N Engl J Med 1992;7:455-465.
13. Di Bartolomeo M, Zampino MG, Di Leo, Bajetta E: Epirubicin, etoposide and cisplatin in advanced pancreatic carcinoma. Eur J Cancer 1993;8:1215-1216.
14. De Caprio JA, Mayer RJ, Gonin R, Arbuck SG: Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: Results of a phase II trial. J Clin Oncol 1991;9:2128-2133.
15. Calabresi F, Repetto M: Doxifluridinc in advanced colorectal cancer. J Surg Oncol 1991;2: 124-128.
16. Alberto P, Winkelmann JJ, Paschoud N, Pey-tremann R, Bruyere A, Righetti A, Decosters G, Holdener H: Phase I study of oral doxifluri-dine using two schedules. Eur J Cancer 1989; 25:905-908.
17. Schmitz SH, Voliotis DL, Schimke J, Diehl V: Continuous 5-fluorouracil and leucovorin as a second-line therapy for advanced gastric carcinoma. Oncology 1994;51:502-506.
18. Vanhoefer U, Wilke H, Weh HJ, Clerens H, Harstrick A, Stahl M, Hossfeld DK, Seeber S: Weekly high-dose 5-fluorouracil and folinic acid as salvage treatment in advanced gastric cancer. Ann Oncol 1994;5:850-851.
19. Moynihan T, Hansen R, Anderson T, Quebbe-man E, Beatty P. Ausman R, Ritch P, Chitam-bar C, Vukclik M: Continuous 5-fluorouracil infusion in advanced gastric carcinoma. Am J Clin Oncol 1988;11:461-464.
20. Cullinan S, Moertel CG, Wieand HS, Schutt A, Krook J, Foley JF, Norris B, Kardinal CG, Tschetter LK, Barlow JF: A phase III trial on the therapy of advanced pancreatic carcinoma. Cancer 1990;65:2207-2212.